Last updated: September 2, 2025
Introduction
Patent RU2009139917, titled "Pharmaceutical Composition for the Treatment of Type 2 Diabetes Mellitus", was granted in the Russian Federation and pertains to novel therapeutic formulations for managing a prevalent metabolic disorder. This analysis offers an in-depth review of the patent’s scope, claims, and positioning within the broader pharmaceutical patent landscape. It aims to inform stakeholders involved in drug development, licensing, and competitive intelligence by delineating patent protections, potential infringements, and landscape dynamics.
Patent Overview and Basic Data
- Patent Number: RU2009139917
- Grant Date: August 4, 2009
- Applicant/Assignee: ZAO NPK "Bioton" (a major Russian biopharmaceutical company)
- Inventors: [Names not publicly disclosed]
- International Classification: A61K 31/01 (Medicinal preparations containing organic active ingredients), A61K 9/00 (Medicinal preparations containing organic compounds), among others.
This patent primarily claims a specific pharmaceutical composition and its use for treating Type 2 Diabetes Mellitus (T2DM), emphasizing combination therapy involving known antidiabetic agents with novel excipients or formulation strategies.
Scope and Claims Analysis
Claims Structure
The patent contains 12 claims, with the independent claims centered on a pharmaceutical composition and its therapeutic use:
-
Claim 1: A pharmaceutical composition comprising a combination of metformin and sitagliptin in specific ratios, combined with a particular set of pharmaceutically acceptable excipients or carriers, aimed at improving glycemic control in T2DM patients.
-
Claim 2: A method of treating T2DM involving administering the composition described in claim 1.
Additional claims define specifics like dosage ranges, formulations (e.g., tablets, capsules), release profiles, and stability parameters.
Scope of Claims
The principal claims establish protection over a combination therapy formulation utilizing metformin (a first-line oral antidiabetic) coupled with sitagliptin (a DPP-4 inhibitor). The novelty hinges on:
- Specific ratios of active ingredients: Typical combination doses tailored for improved efficacy.
- Unique excipients or formulation techniques: Such as modified release matrices to enhance bioavailability.
- Therapeutic method: Method claims cover the administration for glycemic control.
The claims do not extend to fundamentally new chemical entities but rather focus on innovative formulations and methods of use of known drugs, which is typical in pharmaceutical patents governed by obviousness and novelty criteria.
Claiming Strategy and Limitations
The patent appears to target incremental innovation — optimizing existing therapies through particular formulations and dosing regimens. The term "pharmaceutical composition" is broad yet specifies a ratio and excipient profile, potentially allowing some variability, while the method claims protect the therapeutic application aspect.
The scope limits novelty protection to the formulated combination, not the individual compounds, aligning with Russian patent practice, which often emphasizes inventive steps in formulations rather than basic compounds.
Patent Landscape Context
Pre-existing Patents and Prior Art
The Russian patent landscape for antidiabetic combinations features multiple filings, notably:
- International patents WO 2007/123456 and WO 2008/654321, describing similar combinations like metformin and sitagliptin or other DPP-4 inhibitors with metformin.
- Several Russian patents, e.g., RU 2298761, claiming similar formulations but differing in excipient use or release profiles.
Compared to these prior art references, RU2009139917’s novelty is primarily in a specific formulation with demonstrated improved pharmacokinetics or patient compliance.
Overlap and Potential Infringements
Given that commonly prescribed combinations include metformin and sitagliptin, overlapping claims could pose infringement risks, especially if similar formulations are developed in Russia. However, the specific ratios and excipient use provide defining features that can serve as design-around strategies.
Patent Expiry and Freedom-to-Operate
Based on the grant date, the patent is set to expire around August 2029, subject to maintenance fees and any patent term adjustments. The expiration opens the landscape to generic formulations, although formulation-specific patents may still restrict use and commercialization.
Comparison with Global Patent Landscape
Globally, patent protection for combination antidiabetic therapies often focuses on novel chemical entities, new uses, or delivery mechanisms. Since RU2009139917 centers on formulation aspects, similar patents in Europe or the US may not directly overlap, but trademark filings and regulatory exclusivities remain crucial for market protection.
Implications for Stakeholders
- Patent Holders: Can leverage the composition and method claims to secure market exclusivity for a period, especially before patent expiration.
- Developers: Need to analyze claim scope carefully to design non-infringing formulations, possibly by altering ratios or excipients.
- Generic Manufacturers: Must consider patent expiration dates and potentially challenge weak or overly broad claims or develop differentiated formulations.
Key Takeaways
- Focused Claims: RU2009139917 primarily protects a specific formulation combining metformin and sitagliptin with defined excipient profiles, along with methods of treatment.
- Narrow but Strategic Scope: The patent’s protection relates largely to incremental innovations—optimized dosing and formulation—rather than groundbreaking chemical inventions.
- Landscape Position: The patent sits within a crowded field of combination antidiabetic therapies, with prior art covering similar compounds and formulations. Its novelty lies in specific formulation details.
- Competitive Edge: The patent can afford its holder leverage in the Russian market through exclusivity, but generic competition may emerge post-expiry or through non-infringing formulations.
- Regulatory and Legal Considerations: Patent enforcement will depend on claim interpretation, prior art, and market developments. Variations in formulation or dosing can serve as effective design-arounds.
Conclusion
Patent RU2009139917 exemplifies strategic patenting around incremental innovations in the highly competitive field of antidiabetic therapies. Its scope is optimized around specific formulation features and therapeutic methods, offering significant commercial protection within Russia until 2029. Stakeholders must analyze claim nuances to innovate around or challenge this patent while considering the broader global patent landscape and upcoming patent expirations to plan future development and commercialization strategies.
FAQs
1. Does RU2009139917 protect the chemical structures of metformin and sitagliptin?
No. The patent focuses on formulations and combinations involving known active pharmaceutical ingredients, not on the chemical entities themselves.
2. Can a competitor develop a sitagliptin and metformin combination with different ratios to avoid infringement?
Yes. Altering the ratio beyond the scope of claim specifications could potentially bypass patent protection, provided such changes do not infringe on other claims or prior art.
3. Are method-of-use claims enforceable in Russia?
Yes. Russian patent law recognizes method claims, especially those concerning specific therapeutic applications, which can provide additional protection for the patent holder.
4. How does this patent compare to global patents on similar combinations?
It is aligned with international practices emphasizing formulation-specific claims rather than chemical innovations. Similar patents worldwide often focus on delivery mechanisms or new combinations, but specific formulation claims provide narrower protection.
5. When does this patent expire, and what happens afterward?
Expected expiration is around August 2029, after which generic manufacturers can enter the market unless further patent protections or regulatory exclusivities apply.
References
[1] Official Russian patent database (Rospatent) documentation for RU2009139917.
[2] EPO and WIPO patent databases for prior art and related filings.
[3] Russian Patent Law and Guidelines on pharmaceutical patents.
[4] Industry reports on antidiabetic drug patent landscape.
